newsfilter
← Latest News
GlobeNewswire·

Eliem Therapeutics Reports Third Quarter Financial and Business Highlights

Positioned to initiate ETX-155 Phase 2a trial in major depressive disorder in the first quarter of 2023 with 60-milligram dose Progressing IND-enabling studies for two Kv7 pre-candidates with safety studies planned in